https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMTEzMjM1MS1vdmVydmlldw==
Drugs & Diseases > Dermatology
Dermatologic Manifestations of Herpes Simplex
Author: Sean P McGregor, DO, PharmD; Chief Editor: William D James, MD more...
Sections Dermatologic Manifestations of Herpes Simplex
Laboratory Studies
Histologic Findings
Herpes simplex viruses (HSVs) are linear double-stranded DNA viruses that cause acute skin infections and present as grouped vesicles on an erythematous base. Rarely, these viruses can cause serious illness and can affect pregnancy, leading to significant harm to the fetus. Most infections are recurrent and tend to reappear at or near the same location. Herpes labialis is the most common infection caused by HSV type 1 (HSV-1), whereas genital herpes is usually caused by HSV type 2 (HSV-2). Other clinical manifestations of HSV infection are less common.
Characteristic cluster of vesicles on an erythematous base. Photo courtesy of Dr. John Reeves.
Intimate contact between a susceptible person (without antibodies against the virus) and an individual who is actively shedding the virus or with body fluids containing the virus is required for herpes simplex virus (HSV) infection to occur. Viral shedding occurs during the primary infection, during subsequent recurrences, and during periods of asymptomatic viral shedding. Contact during these periods must involve mucous membranes or open or abraded skin. Following exposure, the primary infection of HSV is established at the site of contact. Here, the viral envelope is fused with the cellular membranes of the skin and mucous membranes and HSV DNA is incorporated into the nucleus. [1] HSV glycoprotein C protects the viral envelope and aids in viral entry. [2] Recognition of HSV DNA by Toll-like receptors results in the activation of the innate and adaptive immune systems and production of interferon gene products. [1] Viral suppression of host cell immune responses and subsequent evasion of the immune system is accomplished via a complex interplay between HSV virion protein products and the immune system. Specifically, the HSV protein, virion host shutoff (VHS), is produced in the early stages of infection to suppress host cell responses. [1] Additionally, glycoprotein C binds to complement C3b, inhibiting complement-mediated immunity and plays a role in inhibiting antibody neutralization. [2] HSV then invades and replicates in neurons as well as in epidermal and dermal cells. Virions travel from the initial site of infection on the skin or mucosa to the sensory dorsal root ganglion, where latency is established. The latent state is established by silencing of the HSV genome in neurons, and reactivation can occur during periods of stress.
Viral replication in the sensory ganglia leads to recurrent clinical outbreaks. These outbreaks can be induced by various stimuli, such as trauma, ultraviolet (UV) radiation, extremes in temperature, stress, immunosuppression, surgical and laser procedures, or hormonal fluctuations. HSV-specific CD8+ T cells appear to play an important role in controlling recurrent infections and reactivation. [3] CD8+ T cells are primed and recruited by innate and adaptive immune responses during the primary infection. The chemokine receptors, CXCR3 and CCR10, have been found to be up-regulated in HSV-specific CD8+ T cells and may contribute to homing mechanisms and control of inflammation during periods of reactivation. [3]
HSV-1 reactivation occurs most efficiently from trigeminal ganglia (affecting the face and the oropharyngeal and ocular mucosae), while HSV-2 has a more efficient reactivation in the lumbosacral ganglia (affecting the hips, buttocks, genitalia, and lower extremities). The clinical difference in site-specific reactivation between HSV-1 and HSV-2 appears to be due, in part, to each virus establishing latent infection in different populations of ganglionic neurons. [4]
Herpes simplex virus (HSV) type 1 and HSV-2 are the causative agents of herpes genitalis, herpes labialis, herpes gladiatorum, herpetic whitlow, herpetic keratoconjunctivitis, eczema herpeticum, herpes folliculitis, lumbosacral herpes, disseminated herpes, neonatal herpes, and herpes encephalitis. [5] They have also been linked to some cases of erythema multiforme. In pediatric patients, HSV infection is associated with 18% of cases of erythema multiforme. [6] A febrile illness, exposure to UV light, trauma, upper respiratory infection, or emotional stress may trigger recurrent herpes labialis due to HSV-1.
The patient's geographical location, socioeconomic status, and age influence the frequency of HSV-1 infections. The highest prevalence of antibodies to HSV-2 occurs in female prostitutes, male homosexuals, and HIV-positive individuals.
Herpes simplex virus (HSV) type 1 infection is typically acquired by early childhood. The seroprevalence of HSV-1 in persons aged 14-49 years in the United States is 53.9%, based on data from the 2005-2010 National Health and Nutrition Examination Survey (NHANES). [7] Only about 30% of these individuals have clinically apparent outbreaks. The seroprevalence of HSV-2 in the United States is 15.7%, and more than 80% of these infections are either asymptomatic or unrecognized. [7, 8] Regardless, these individuals still have episodes of viral shedding and can transmit the virus. The seroprevalence of HSV-1 has declined approximately 7% from prior NHANES data. However, the seroprevalence of HSV-2 has remained stable after increasing between 1976 and 1980 and subsequently declining between 1988 and 2004. [8] Independent predictors of HSV-2 seropositivity include female sex, older age, non-Hispanic black race, and increased lifetime sex partners. [8, 9] Additionally, patients with prior sexually transmitted infections, such as chlamydia, gonorrhea, and syphilis, have higher rates of HSV-2 seroprevalence. [10] Newer data indicate that HSV-1 infections may account for more genital infections than previously thought. A retrospective review of genital HSV infection in college-age students revealed that HSV-1 accounted for 78% of isolates, suggesting a reversal in prior etiologic notions. [11]
Serologic evidence of HSV infection varies by country. [12, 13] The seroprevalence of HSV-1 is 78.4% in Germany, whereas, it is 42.7% in the Netherlands. [14, 15] A study of two cities in Italy on the prevalence of HSV-1 and HSV-2 from 2000-2014 showed a significant decline in the study population (14.5% decrease in women; 22% decrease in men) for HSV-1 infection and a decline in HSV-2 infection from 22.4% to 11.5%. [16] Similar findings have been seen in the United States.
Worldwide, the seroprevalence of HSV-1 and HSV-2 is 67% and 11.3%, respectively. [17, 18] As in the United States, HSV-1 prevalence increases with advancing age worldwide. The highest prevalence of HSV-1 and HSV-2 appears to be in Africa. [17, 18]
In the developing world, HSV-2 is becoming a common cause for genital ulcer disease, especially in countries with a high prevalence of HIV infection. [19] International studies show seroprevalence in people co-infected with HIV being close to 90% for HSV-1 and up to 77% for HSV-2. [20]
The seroprevalence of HSV-2 in the United States is approximately three-fold higher in non-Hispanic blacks as compared with non-Hispanic whites. [8] Seroprevalence is highest among older non-Hispanic blacks, affecting approximately 56% of patients aged 30-49 years. [8] In contrast, the seroprevalence of HSV-1 in patients aged 14-19 years has declined from 55.7% (between 1999 and 2004) to 39.6% (between 2005 and 2010) in the non-Hispanic black population, but it has remained stable, at approximately 58%, in the Mexican American population. [7] Additionally, the seroprevalence of HSV-1 in foreign-born patients in the United States is higher than in patients born in the United States [7]
The frequency of HSV-1 antibodies is slightly higher in females than in males (33.2% vs 27.1%). [7] In a study of more than 600 pregnant women, 63% were seropositive for HSV-1, 22% for HSV-2, and 13% for both, and 28% were seronegative. Nonwhite race and having had four or more sexual partners independently correlated with increased HSV-2 infection. Non-Hispanic white pregnant women had the highest percentage of seronegativity for both HSV-1 and HSV-2. However, this group had the highest risk of having a child with neonatal herpes, indicating their susceptibility for new HSV infection during their third trimester of pregnancy (when a mother is most likely to transmit infection to her neonate). [21]
Socioeconomic factors appear to play a substantial role as well. Seropositivity for HSV-2 has been shown to be as high as 88% in homeless women or women with unstable housing. [22] Associated risk factors in this population were alcohol use, heterosexual orientation, HIV infection, and lower income status. [22]
Overall, the seroprevalence of HSV-1 and HSV-2 increase with increasing age. From 2005-2010, the seroprevalence of HSV-1 among patients aged 14-19 years was 30.1% and 63.6% among patients aged 40-49 years. [7] Similar trends exist for HSV-2 seroprevalence, with 1.2% of persons aged 14-19 years affected and 25.6% of those aged 40-49 years affected. [7] The frequency of HSV-1 infection in children also varies with socioeconomic status. Approximately, one third of children from families of lower socioeconomic status exhibit some evidence of HSV-1 infection by age 5 years. A retrospective review of HSV cases from pediatric dermatology clinics found the average age of presentation to be 6 years and 33% of patients presented at age 2 years or younger. [23] Approximately 40% of these children had a history of atopy and experienced six or more outbreaks per year. [23] Triggers included UV light exposure, cold weather, and systemic corticosteroids for asthma. [23]
For most people, herpes simplex virus (HSV) infections are temporary and resolve without detrimental sequelae; however, recurrence is common. The associated pain, paresthesia, and discomfort, as well as the psychosocial impact, of herpes simplex outbreaks cause significant morbidity to the individuals who are affected. Long-term sequelae (usually CNS) are more common with neonatal HSV infection than with other types of HSV infection. Scarring may occur from severe or superinfected lesions.
Mortality/morbidity
Severe complications may be associated with herpes simplex. This is especially true in females who are pregnant and in individuals with immunosuppression, who may develop disseminated infection and encephalitis.
Complications of HSV-1 infections vary based on the site of involvement and whether the patient is immunocompromised. HSV-1 infections of the oral mucosa result in gingivostomatitis in children and pharyngitis in adults. Reactivation of infections of the oral mucosa present as herpes labialis and are less severe than the primary infection. HSV-1 can also infect any cutaneous surface. Patients with Darier disease, atopic dermatitis, or mycosis fungoides may develop life-threatening eczema herpeticum (Kaposi varicelliform eruption). Organ transplant recipients and patients with HIV/AIDS may develop herpetic lesions that exhibit an unusual morphology. Additionally, HSV DNA has been associated with erythema multiforme in approximately 43% of cases. [24]
Ocular and neurologic sequelae of HSV-1 infection include conjunctivitis, blepharitis, keratitis, acute retinal necrosis, Bell palsy, and encephalitis. Herpes simplex keratitis is characterized by ocular pain and is a common infectious cause of unilateral vision loss. [25] Clinical manifestations of HSV-1 encephalitis include fever, headache, nausea, vomiting, seizures, confusion, and focal deficits. [26] Approximately 15% of hospitalized patients die from HSV encephalitis, and survivors have long-term disability affecting cognitive function. [26]
The most common complication of primary HSV-2 genital infection is bacterial superinfection. Extragenital complications such as urinary retention, aseptic meningitis, and proctitis can occur in patients with HSV-2. Urinary retention and aseptic meningitis occur more frequently in women. Proctitis due to HSV-2 occurs more commonly in men who have sex with men and accounts for approximately 15% of cases. [27] Additionally, HSV-1 and HSV-2 are more common in men with proctitis and HIV infection than in those without HIV infection. [28]
Individuals co-infected with HSV and HIV and who have herpetic mucosal lesions are more likely to transmit HIV during sexual contact. In studies, despite being compliant with highly active antiretroviral therapy (HAART) for treatment of HIV-1 infection, 30-50% of women co-infected with HSV-2 and HIV-1 were shown to have genital HIV-1 shedding at least once in a 3-month period. Studies also suggest that co-infection with HSV-2 may accelerate HIV disease progression by elevating the HIV viral load. A 2008 study by Baeten et al found that HSV suppressive therapy decreased genital and plasma HIV levels in women with HSV-2/HIV co-infection. [29]
Another serious consequence of HSV infection is transmission of the virus to a neonate by a mother who is infected. [30] Asymptomatic maternal shedding occurs approximately 7% of the time and is responsible for most neonatal HSV infections. The risk of HSV transmission to the newborn is as high as 30-50% from a mother who acquired a new HSV infection near the time of delivery. Among women who have acquired HSV infection before their third trimester of pregnancy, the risk of transmission is less than 1%. HSV infections in neonates are most commonly due to HSV-2 and most are acquired peripartum from exposure to lesions (or shedding virus) in the birth canal, although in utero and postpartum transmission can rarely occur. Transmission is estimated to occur at a rate of 1 case in 3500-5000 deliveries in the United States. Neonatal infection can cause long-term sequelae and even death.
Reported in 2019, HSV-1 has been implicated in the pathogenesis of Alzheimer disease. HSV-1 has been shown to cause intracellular accumulation of amyloid-β protein (Aβ), which is involved in the pathogenesis of Alzheimer disease. [31] Additionally, patients that are apolipoprotein E carriers who had IgM or high-IgG titers against HSV-1 have an increased risk of Alzheimer disease. [32]
Patients who are immunocompetent should be reassured that the disease does not cause serious harm. However, physical and psychological concerns must be validated, and appropriate counseling is warranted.
For patient education resources, visit the Sexual Health Center, Oral Health Center, and Skin Conditions and Beauty Center. Also, see the patient education articles Genital Herpes, Genital Herpes in Woman, Oral Herpes, and Eczema.
Roizman B, Whitley RJ. An inquiry into the molecular basis of HSV latency and reactivation. Annu Rev Microbiol. 2013. 67:355-74. [Medline].
Komala Sari T, Gianopulos KA, Nicola AV. Glycoprotein C of Herpes Simplex Virus 1 Shields Glycoprotein B from Antibody Neutralization. J Virol. 2020 Feb 14. 94 (5):[Medline].
Hensel MT, Peng T, Cheng A, De Rosa SC, Wald A, Laing KJ, et al. Selective Expression of CCR10 and CXCR3 by Circulating Human Herpes Simplex Virus-Specific CD8 T Cells. J Virol. 2017 Oct 1. 91 (19):[Medline].
Margolis TP, Imai Y, Yang L, Vallas V, Krause PR. Herpes simplex virus type 2 (HSV-2) establishes latent infection in a different population of ganglionic neurons than HSV-1: role of latency-associated transcripts. J Virol. 2007 Feb. 81(4):1872-8. [Medline].
Weinberg JM, Mysliwiec A, Turiansky GW, Redfield R, James WD. Viral folliculitis. Atypical presentations of herpes simplex, herpes zoster, and molluscum contagiosum. Arch Dermatol. 1997 Aug. 133(8):983-6. [Medline].
Zoghaib S, Kechichian E, Souaid K, Soutou B, Helou J, Tomb R. Triggers, clinical manifestations, and management of pediatric erythema multiforme: A systematic review. J Am Acad Dermatol. 2019 Sep. 81 (3):813-822. [Medline].
Bradley H, Markowitz LE, Gibson T, McQuillan GM. Seroprevalence of herpes simplex virus types 1 and 2--United States, 1999-2010. J Infect Dis. 2014 Feb 1. 209 (3):325-33. [Medline].
Centers for Disease Control and Prevention (CDC). Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2010 Apr 23. 59 (15):456-9. [Medline].
Centers for Disease Control and Prevention. 2016 Sexually Transmitted Diseases Surveillance - Other Sexually Transmitted Diseases. Available at https://www.cdc.gov/std/stats16/other.htm. September 26, 2017; Accessed: December 5, 2017.
Gottlieb SL, Douglas JM Jr, Schmid DS, Bolan G, Iatesta M, Malotte CK, et al. Seroprevalence and correlates of herpes simplex virus type 2 infection in five sexually transmitted-disease clinics. J Infect Dis. 2002 Nov 15. 186 (10):1381-9. [Medline].
Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex Transm Dis. 2003 Oct. 30 (10):797-800. [Medline].
Hellenbrand W, Thierfelder W, Müller-Pebody B, Hamouda O, Breuer T. Seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in former East and West Germany, 1997-1998. Eur J Clin Microbiol Infect Dis. 2005 Feb. 24(2):131-5. [Medline].
Singh AE, Romanowski B, Wong T, Gourishankar S, Myziuk L, Fenton J, et al. Herpes simplex virus seroprevalence and risk factors in 2 Canadian sexually transmitted disease clinics. Sex Transm Dis. 2005 Feb. 32(2):95-100. [Medline].
Korr G, Thamm M, Czogiel I, Poethko-Mueller C, Bremer V, Jansen K. Decreasing seroprevalence of herpes simplex virus type 1 and type 2 in Germany leaves many people susceptible to genital infection: time to raise awareness and enhance control. BMC Infect Dis. 2017 Jul 6. 17 (1):471. [Medline].
Woestenberg PJ, Tjhie JH, de Melker HE, van der Klis FR, van Bergen JE, van der Sande MA, et al. Herpes simplex virus type 1 and type 2 in the Netherlands: seroprevalence, risk factors and changes during a 12-year period. BMC Infect Dis. 2016 Aug 2. 16:364. [Medline].
Marchi S, Trombetta CM, Gasparini R, Temperton N, Montomoli E. Epidemiology of herpes simplex virus type 1 and 2 in Italy: a seroprevalence study from 2000 to 2014. J Prev Med Hyg. 2017 Mar. 58 (1):E27-E33. [Medline].
Looker KJ, Magaret AS, May MT, Turner KM, Vickerman P, Gottlieb SL, et al. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS One. 2015. 10 (10):e0140765. [Medline].
Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM. Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012. PLoS One. 2015. 10 (1):e114989. [Medline].
Paz-Bailey G, Ramaswamy M, Hawkes SJ. Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect. 2007 Feb. 83(1):16-22. [Medline]. [Full Text].
Levett PN. Seroprevalence of HSV-1 and HSV-2 in Barbados. Med Microbiol Immunol. 2005 Jan. 194(1-2):105-7. [Medline].
Xu F, Markowitz LE, Gottlieb SL, Berman SM. Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States. Am J Obstet Gynecol. 2007 Jan. 196(1):43.e1-6. [Medline].
Kelly JD, Cohen J, Grimes B, Philip SS, Weiser SD, Riley ED. High Rates of Herpes Simplex Virus Type 2 Infection in Homeless Women: Informing Public Health Strategies. J Womens Health (Larchmt). 2016 Aug. 25 (8):840-5. [Medline].
Gittler JK, Mu EW, Orlow SJ. Characterization of Herpes Simplex Virus Infections Seen in the Pediatric Dermatology Office. Pediatr Dermatol. 2017 Jul. 34 (4):446-449. [Medline].
Ng PP, Sun YJ, Tan HH, Tan SH. Detection of herpes simplex virus genomic DNA in various subsets of Erythema multiforme by polymerase chain reaction. Dermatology. 2003. 207 (4):349-53. [Medline].
Austin A, Lietman T, Rose-Nussbaumer J. Update on the Management of Infectious Keratitis. Ophthalmology. 2017 Nov. 124 (11):1678-1689. [Medline].
Rabinstein AA. Herpes Virus Encephalitis in Adults: Current Knowledge and Old Myths. Neurol Clin. 2017 Nov. 35 (4):695-705. [Medline].
Klausner JD, Kohn R, Kent C. Etiology of clinical proctitis among men who have sex with men. Clin Infect Dis. 2004 Jan 15. 38 (2):300-2. [Medline].
Bissessor M, Fairley CK, Read T, Denham I, Bradshaw C, Chen M. The etiology of infectious proctitis in men who have sex with men differs according to HIV status. Sex Transm Dis. 2013 Oct. 40 (10):768-70. [Medline].
Baeten JM, Strick LB, Lucchetti A, Whittington WL, Sanchez J, Coombs RW, et al. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial. J Infect Dis. 2008 Dec 15. 198(12):1804-8. [Medline]. [Full Text].
Bruno E, Pillus D, Cheng D, Vilke G, Pokrajac N. During the Emergency Department Evaluation of a Well-Appearing Neonate with Fever, Should Empiric Acyclovir Be Initiated?. J Emerg Med. 2017 Nov 29. [Medline].
Li Puma DD, Piacentini R, Leone L, Gironi K, Marcocci ME, De Chiara G, et al. Herpes Simplex Virus Type-1 Infection Impairs Adult Hippocampal Neurogenesis via Amyloid-β Protein Accumulation. Stem Cells. 2019 Nov. 37 (11):1467-1480. [Medline].
Linard M, Letenneur L, Garrigue I, Doize A, Dartigues JF, Helmer C. Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease. Alzheimers Dement. 2020 Jan. 16 (1):200-208. [Medline].
Boivin G, Goyette N, Sergerie Y, Keays S, Booth T. Longitudinal evaluation of herpes simplex virus DNA load during episodes of herpes labialis. J Clin Virol. 2006 Dec. 37(4):248-51. [Medline].
Dabestani N, Katz DA, Dombrowski J, Magaret A, Wald A, Johnston C. Time Trends in First-Episode Genital Herpes Simplex Virus Infections in an Urban Sexually Transmitted Disease Clinic. Sex Transm Dis. 2019 Dec. 46 (12):795-800. [Medline].
Ren Z, Silverberg JI. Association of Atopic Dermatitis With Bacterial, Fungal, Viral, and Sexually Transmitted Skin Infections. Dermatitis. 2020 Feb 10. [Medline].
Hsu DY, Shinkai K, Silverberg JI. Epidemiology of Eczema Herpeticum in Hospitalized U.S. Children: Analysis of a Nationwide Cohort. J Invest Dermatol. 2018 Feb. 138 (2):265-272. [Medline].
Seegräber M, Worm M, Werfel T, Svensson A, Novak N, Simon D, et al. Recurrent eczema herpeticum - a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2019 Nov 16. [Medline].
Hemani SA, Edmond MB, Jaggi P, Cooley A. Frequency and Clinical Features Associated With Eczema Herpeticum in Hospitalized Children With Presumed Atopic Dermatitis Skin Infection. Pediatr Infect Dis J. 2020 Feb 14. [Medline].
Konda D, Chandrashekar L, Dhodapkar R, Ganesh RN, Thappa DM. Clinical Markers of Herpes Simplex Virus Infection in Patients with Pemphigus Vulgaris. J Am Acad Dermatol. 2019 Jun 10. [Medline].
Foti C, Filotico R, Calvario A, Conserva A, Antelmi A, Angelini G. Relapsing herpes simplex-2 folliculitis in the beard area. Eur J Dermatol. 2004 Nov-Dec. 14(6):421-3. [Medline].
Pomerantz H, Wang H, Heilman ER, Sharon VR, Gottesman SP. Peculiar vegetative tumor-like genital herpes simplex nodules with brisk tissue eosinophilia in patients with human immunodeficiency virus infection. J Cutan Pathol. 2020 Feb. 47 (2):150-153. [Medline].
Sasso BM, Florence MEB, Magalhaes RF, Velho PENF, de Souza EM, Cintra ML, et al. Herpes simplex virus mucocutaneous tumoural lesions - Systematic review. J Clin Virol. 2020 Feb. 123:104246. [Medline].
Fernandes ND, Sthapit B, Mhanna M, Abughali N. Evaluation of suspected neonatal herpes simplex virus infection in preterm versus term newborns in the neonatal intensive care unit. J Neonatal Perinatal Med. 2020 Feb 20. [Medline].
Davis A, Gaynor A. Testing for Sexually Transmitted Diseases in US Public Health Laboratories, 2016. Sex Transm Dis. 2020 Feb. 47 (2):122-127. [Medline].
Faron ML, Ledeboer NA, Patel A, Beqa SH, Yen-Lieberman B, Kohn D, et al. Multicenter Evaluation of Meridian Bioscience HSV 1&2 Molecular Assay for Detection of Herpes Simplex Virus 1 and 2 from Clinical Cutaneous and Mucocutaneous Specimens. J Clin Microbiol. 2016 Aug. 54 (8):2008-13. [Medline].
Swenson PD, El-Sabaeny A, Thomas-Moricz V, Allen M, Groskopf A, Jiang A, et al. Evaluation of a transcription mediated amplification assay for detection of herpes simplex virus types 1 and 2 mRNA in clinical specimens. J Clin Virol. 2016 Jul. 80:62-7. [Medline].
Ramaswamy M, McDonald C, Smith M, Thomas D, Maxwell S, Tenant-Flowers M, et al. Diagnosis of genital herpes by real time PCR in routine clinical practice. Sex Transm Infect. 2004 Oct. 80 (5):406-10. [Medline].
[Guideline] Centers for Disease Control and Prevention. 2015 Sexually Transmitted Diseases Treatment Guidelines. Available at https://www.cdc.gov/std/tg2015/default.htm. January 25, 2017; Accessed: December 5, 2017.
Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol Vis Sci. 2005 Jan. 46(1):241-7. [Medline].
Laggis C, Wada D, Shah A, Zussman J. Eosinophils are surprisingly common in biopsy specimens of cutaneous herpes simplex virus and varicella zoster virus infections: Results of a comprehensive histopathologic and clinical appraisal. J Cutan Pathol. 2020 Jan. 47 (1):6-11. [Medline].
Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. BMJ. 1997 Jun 21. 314 (7097):1800-3. [Medline].
Spruance SL, Bodsworth N, Resnick H, Conant M, Oeuvray C, Gao J, et al. Single-dose, patient-initiated famciclovir: a randomized, double-blind, placebo-controlled trial for episodic treatment of herpes labialis. J Am Acad Dermatol. 2006 Jul. 55 (1):47-53. [Medline].
Baker D, Eisen D. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies. Cutis. 2003 Mar. 71 (3):239-42. [Medline].
Benedetti J, Corey L, Ashley R. Recurrence rates in genital herpes after symptomatic first-episode infection. Ann Intern Med. 1994 Dec 1. 121 (11):847-54. [Medline].
Gupta R, Warren T, Wald A. Genital herpes. Lancet. 2007 Dec 22. 370 (9605):2127-37. [Medline].
Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004 Jan 1. 350 (1):11-20. [Medline].
Abudalu M, Tyring S, Koltun W, Bodsworth N, Hamed K. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin Infect Dis. 2008 Sep 1. 47 (5):651-8. [Medline].
Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis. 2004 Nov 1. 39 Suppl 5:S248-57. [Medline].
Epstein JB, Gharapetian S, Rejali AR, Zabner R, Lill M, Tzachanis D. Complex management of resistant oral herpes simplex virus infection following hematopoietic stem cell transplantation: potential role of topical cidofovir. Support Care Cancer. 2016 Aug. 24 (8):3603-6. [Medline].
Muluneh B, Dean A, Armistead P, Khan T. Successful clearance of cutaneous acyclovir-resistant, foscarnet-refractory herpes virus lesions with topical cidofovir in an allogeneic hematopoietic stem cell transplant patient. J Oncol Pharm Pract. 2013 Jun. 19 (2):181-5. [Medline].
Mark KE, Spruance S, Kinghorn GR, Sacks SL, Slade HB, Meng TC, et al. Three phase III randomized controlled trials of topical resiquimod 0.01-percent gel to reduce anogenital herpes recurrences. Antimicrob Agents Chemother. 2014 Sep. 58 (9):5016-23. [Medline].
Subramaniam A, Britt WJ. Herpesviridae Infection: Prevention, Screening, and Management. Clin Obstet Gynecol. 2018 Mar. 61 (1):157-176. [Medline].
Spruance SL, Nett R, Marbury T, Wolff R, Johnson J, Spaulding T. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. Antimicrob Agents Chemother. 2002 Jul. 46 (7):2238-43. [Medline].
Hull CM, Harmenberg J, Arlander E, Aoki F, Bring J, Darpö B, et al. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: A randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol. 2011 Apr. 64(4):696.e1-696.e11. [Medline].
Sacks SL, Thisted RA, Jones TM, Barbarash RA, Mikolich DJ, Ruoff GE, et al. Clinical efficacy of topical docosanol 10% cream for herpes simplex labialis: A multicenter, randomized, placebo-controlled trial. J Am Acad Dermatol. 2001 Aug. 45 (2):222-30. [Medline].
Silverberg NB, Durán-McKinster C. Special Considerations for Therapy of Pediatric Atopic Dermatitis. Dermatol Clin. 2017 Jul. 35 (3):351-363. [Medline].
Tatnall FM, Schofield JK, Leigh IM. A double-blind, placebo-controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol. 1995 Feb. 132 (2):267-70. [Medline].
Rooney JF, Bryson Y, Mannix ML, Dillon M, Wohlenberg CR, Banks S, et al. Prevention of ultraviolet-light-induced herpes labialis by sunscreen. Lancet. 1991 Dec 7. 338 (8780):1419-22. [Medline].
Shamsaldeen O, Peterson JD, Goldman MP. The adverse events of deep fractional CO(2): a retrospective study of 490 treatments in 374 patients. Lasers Surg Med. 2011 Aug. 43 (6):453-6. [Medline].
Bisaccia E, Scarborough D. Herpes simplex virus prophylaxis with famciclovir in patients undergoing aesthetic facial CO2 laser resurfacing. Cutis. 2003 Oct. 72 (4):327-8. [Medline].
Hosken NA. Development of a therapeutic vaccine for HSV-2. Vaccine. 2005 Mar 18. 23(17-18):2395-8. [Medline].
Awasthi S, Hook LM, Shaw CE, Friedman HM. A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model. Hum Vaccin Immunother. 2017 Dec 2. 13 (12):2785-2793. [Medline].
Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002 Nov 21. 347(21):1652-61. [Medline].
Du R, Wang L, Xu H, Wang Z, Zhang T, Wang M, et al. A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus. Antiviral Res. 2017 Nov. 147:131-141. [Medline].
Gupta R, Wald A, Krantz E, Selke S, Warren T, Vargas-Cortes M, et al. Valacyclovir and acyclovir for suppression of shedding of herpes simplex virus in the genital tract. J Infect Dis. 2004 Oct 15. 190(8):1374-81Epub 2004 Sep 20. [Medline].
Mayaud P, Legoff J, Weiss HA, Grésenguet G, Nzambi K, Bouhlal H, et al. Impact of acyclovir on genital and plasma HIV-1 RNA, genital herpes simplex virus type 2 DNA, and ulcer healing among HIV-1-infected African women with herpes ulcers: a randomized placebo-controlled trial. J Infect Dis. 2009 Jul 15. 200(2):216-26. [Medline].
Nagot N, Ouedraogo A, Konate I, Weiss HA, Foulongne V, Defer MC, et al. Roles of clinical and subclinical reactivated herpes simplex virus type 2 infection and human immunodeficiency virus type 1 (HIV-1)-induced immunosuppression on genital and plasma HIV-1 levels. J Infect Dis. 2008 Jul 15. 198(2):241-9. [Medline].
Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC, et al. Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS. 2006 Nov 28. 20(18):2305-13. [Medline].
Scott LL, Hollier LM, McIntire D, Sanchez PJ, Jackson GL, Wendel GD. Acyclovir suppression to prevent clinical recurrences at delivery after first episode genital herpes in pregnancy: an open-label trial. Infect Dis Obstet Gynecol. 2001. 9(2):75-80. [Medline].
Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA. 2010 Aug 25. 304(8):859-66. [Medline].
Lee R, Nair M. Diagnosis and treatment of herpes simplex 1 virus infection in pregnancy. Obstet Med. 2017 Jun. 10 (2):58-60. [Medline].
Barclay L. ACOG recommends expedited partner therapy for STIs. Medscape Medical News. Available at http://www.medscape.com/viewarticle/845221. May 22, 2015; Accessed: June 24, 2015.
[Guideline] American College of Obstetricians and Gynecologists. Committee opinion no 632: expedited partner therapy in the management of gonorrhea and chlamydial infection. Obstet Gynecol. 2015 Jun. 125 (6):1526-8. [Medline].
Sean P McGregor, DO, PharmD Resident Physician, Department of Dermatology, Baptist Health Medical Center, Wake Forest University School of Medicine
Sean P McGregor, DO, PharmD is a member of the following medical societies: American Academy of Dermatology, American Osteopathic College of Dermatology, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery, American Society of Health-System Pharmacists, Sigma Sigma Phi
William W Huang, MD, MPH, FAAD Associate Professor and Residency Program Director, Department of Dermatology, Wake Forest Baptist Health, Wake Forest University School of Medicine
William W Huang, MD, MPH, FAAD is a member of the following medical societies: American Academy of Dermatology, Association of Professors of Dermatology, Dermatology Foundation, Medical Dermatology Society, North Carolina Medical Society, Women's Dermatologic Society
Disclosure: Research PI for Sponsored Trial for: Gilead; Genentech;.
Michael J Wells, MD, FAAD Dermatologic/Mohs Surgeon, The Surgery Center at Plano Dermatology
Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association
Rosalie Elenitsas, MD Herman Beerman Professor of Dermatology, University of Pennsylvania School of Medicine; Director, Penn Cutaneous Pathology Services, Department of Dermatology, University of Pennsylvania Health System
Rosalie Elenitsas, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society of Dermatopathology, Pennsylvania Academy of Dermatology
Disclosure: Received royalty from Lippincott Williams Wilkins for textbook editor.
William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine
William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology
Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD<br/>Served as a speaker for various universities, dermatology societies, and dermatology departments.
Joseph S Eastern, MD Clinical Assistant Professor, Department of Internal Medicine, Section of Dermatology, University of Medicine and Dentistry of New Jersey; Clinical Assistant Professor, Seton Hall University School of Graduate Medical Education
Joseph S Eastern, MD is a member of the following medical societies: American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, International Society for Dermatologic Surgery, Medical Society of New Jersey
Sungnack Lee, MD Vice President of Medical Affairs, Professor, Department of Dermatology, Ajou University School of Medicine, Korea
Sungnack Lee, MD is a member of the following medical societies: American Academy of Dermatology
The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors, Malcolm Schinstine, MD, PhD; Paul Krusinski, MD; Gisela Torres, MD; and Stephen K Tyring, MD, PhD, MBA, to the development and writing of this article.
encoded search term (Dermatologic Manifestations of Herpes Simplex) and Dermatologic Manifestations of Herpes Simplex
Pediatric Herpes Simplex Virus Infection
Herpes Simplex Virus (HSV) Keratitis
Herpes Simplex Virus (HSV) Empiric Therapy
Herpes Simplex Virus (HSV) in Emergency Medicine
Herpes Simplex Encephalitis
Herpes Simplex Encephalitis (HSE) Imaging
Upadacitinib (Rinvoq) Gains Psoriatic Arthritis as Second FDA-Approved Indication
Atopic Dermatitis and the Risk of Infections
Oral Steroid Gets FDA Approval for IgA Nephropathy
5 Common-to-Rare Infant Skin Conditions
Diseases & Conditions Pediatric Herpes Simplex Virus Infection
Diseases & Conditions Herpes Simplex Virus (HSV) in Emergency Medicine
Diseases & Conditions Genital Herpes in Pregnancy